Skip to main content

Table 1 Patient Characteristics (n = 24)

From: Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers

Characteristics

No. of Patients (%)

Age, years

 Median

62

 Range

30–72

Sex

 Male

4 (17)

 Female

20 (83)

Race

 White

22 (90)

 Black

0

 Other

2 (10)

ECOG performance status

 ECOG 0

16 (67)

 ECOG 1

7 (29)

 ECOG 2

1 (4)

Tumor type

 Ovarian/fallopian/peritoneal

10 (42)

 Endometrial

5 (21)

 Cervical

3 (13)

 Esophageal

2 (8)

 Urethral

1 (4)

 Vaginal

1 (4)

 Mesothelial

1 (4)

 Salivary

1 (4)

Prior chemotherapiesa

 0

7 (29)

 1

1 (4)

 2

7 (29)

 3

9 (38)

  1. ECOG Eastern Cooperative Oncology Group
  2. aTherapies that included chemotherapy for radiation sensitization only (n = 4), were discontinued due to toxicity without progression (n = 2), were radiation alone (n = 4), or were hormonal only (n = 2) were not included for eligibility